Lv1
30 积分 2023-12-21 加入
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
1天前
已完结
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview
1个月前
已完结
Opportunities and Challenges of Hepatic Impairment Physiologically Based Pharmacokinetic Modeling in Drug Development—An IQ Perspective
2个月前
已完结
Hepatic Impairment and the Differential Effects on Drug Clearance Mechanisms: Analysis of Pharmacokinetic Changes in Disease State
2个月前
已完结
Physiologically Based Pharmacokinetic Model‐Informed Drug Development for Polatuzumab Vedotin: Label for Drug‐Drug Interactions Without Dedicated Clinical Trials
3个月前
已完结
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses
3个月前
已完结
Evaluating the drug-drug interactions of SHR4640 on repaglinide and midazolam in healthy subjects
3个月前
已完结
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
3个月前
已完结
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
3个月前
已完结
皖公网安备34019202002308
